854 related articles for article (PubMed ID: 19709824)
1. Risks of osteoporosis associated with breast cancer treatment: the need to access to preventive treatment.
Rozenberg S; Carly B; Liebens F; Antoine C
Maturitas; 2009 Sep; 64(1):1-3. PubMed ID: 19709824
[TBL] [Abstract][Full Text] [Related]
2. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
Reid DM; Doughty J; Eastell R; Heys SD; Howell A; McCloskey EV; Powles T; Selby P; Coleman RE
Cancer Treat Rev; 2008; 34 Suppl 1():S3-18. PubMed ID: 18515009
[TBL] [Abstract][Full Text] [Related]
3. Prevention of osteoporosis after breast cancer.
Reid DM
Maturitas; 2009 Sep; 64(1):4-8. PubMed ID: 19709826
[TBL] [Abstract][Full Text] [Related]
4. Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.
Yonehara Y; Iwamoto I; Kosha S; Rai Y; Sagara Y; Douchi T
J Obstet Gynaecol Res; 2007 Oct; 33(5):696-9. PubMed ID: 17845332
[TBL] [Abstract][Full Text] [Related]
5. Aromatase inhibitors and bone health.
Bundred NJ
Curr Opin Obstet Gynecol; 2009 Feb; 21(1):60-7. PubMed ID: 19125005
[TBL] [Abstract][Full Text] [Related]
6. Evaluating bone health in women with oestrogen receptor positive breast cancer (ERBC) starting aromatase inhibitors.
Clunie GP; Clark A; Mortimer CJ; Stephenson S; Aitken J; Smith C; Sherwin E; Archer TJ
Eur J Surg Oncol; 2009 May; 35(5):475-80. PubMed ID: 18950981
[TBL] [Abstract][Full Text] [Related]
7. Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies.
Coleman RE; Body JJ; Gralow JR; Lipton A
Cancer Treat Rev; 2008; 34 Suppl 1():S31-42. PubMed ID: 18486346
[TBL] [Abstract][Full Text] [Related]
8. Osteoporosis risk in premenopausal women.
Vondracek SF; Hansen LB; McDermott MT
Pharmacotherapy; 2009 Mar; 29(3):305-17. PubMed ID: 19249949
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant aromatase inhibitors and bone health.
Chowdhury S; Pickering LM; Ellis PA
J Br Menopause Soc; 2006 Sep; 12(3):97-103. PubMed ID: 16953982
[TBL] [Abstract][Full Text] [Related]
10. Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer.
Hadji P; Bundred N
Semin Oncol; 2007 Dec; 34(6 Suppl 4):S4-10. PubMed ID: 18068489
[TBL] [Abstract][Full Text] [Related]
11. Emerging bone health issues in women with breast cancer in Hawai'i.
Carney JF; Davis J
Hawaii Med J; 2007 Jun; 66(6):164-6. PubMed ID: 17621865
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
Ito K; Blinder VS; Elkin EB
J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
[TBL] [Abstract][Full Text] [Related]
13. Reducing the risk of bone loss associated with breast cancer treatment.
Hadji P
Breast; 2007 Dec; 16 Suppl 3():S10-5. PubMed ID: 18023583
[TBL] [Abstract][Full Text] [Related]
14. Effects of third-generation aromatase inhibitors on bone.
McCloskey E
Eur J Cancer; 2006 May; 42(8):1044-51. PubMed ID: 16554149
[TBL] [Abstract][Full Text] [Related]
15. Prevention of osteoporosis as a consequence of aromatase inhibitor therapy in postmenopausal women with early breast cancer: rationale and design of a randomized controlled trial.
Kilbreath S; Refshauge KM; Beith J; Ward L; Sawkins K; Paterson R; Clifton-Bligh P; Sambrook PN; Simpson JM; Nery L
Contemp Clin Trials; 2011 Sep; 32(5):704-9. PubMed ID: 21570487
[TBL] [Abstract][Full Text] [Related]
16. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
Brufsky A; Bundred N; Coleman R; Lambert-Falls R; Mena R; Hadji P; Jin L; Schenk N; Ericson S; Perez EA;
Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
[TBL] [Abstract][Full Text] [Related]
17. [Measurement of bone mineral density is unnecessary for monitoring of bisphosphonate treatment].
Nishida A; Ito M
Clin Calcium; 2011 Jan; 21(1):120-3. PubMed ID: 21187605
[TBL] [Abstract][Full Text] [Related]
18. [Absolute risk for fracture and WHO guideline. Treatment of patients with secondary osteoporosis].
Yamauchi M;
Clin Calcium; 2007 Jul; 17(7):1106-13. PubMed ID: 17607079
[TBL] [Abstract][Full Text] [Related]
19. Is treatment of early postmenopausal women with bisphosphonates justified?
Epstein S
Int J Clin Pract; 2007 Jun; 61(6):963-71. PubMed ID: 17504359
[TBL] [Abstract][Full Text] [Related]
20. Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy.
Ryan CW; Huo D; Stallings JW; Davis RL; Beer TM; McWhorter LT
Urology; 2007 Jul; 70(1):122-6. PubMed ID: 17656221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
